Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.

被引：24
|
作者：
Sikic, B. I.
Eckhardt, S. G.
Gallant, G.
Burris, H. A.
Camidge, D. R.
Colevas, A. D.
Jones, S. F.
Messersmith, W. A.
Wakelee, H. A.
Li, H.
Kaminker, P. G.
Morris, S.
Infante, J. R.
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Univ Colorado, Sch Med, Aurora, CO USA
[3] Human Genome Sci, Rockville, MD USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Univ Colorado Denver, Aurora, CO USA
[6] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[7] Univ Colorado, Ctr Canc, Aurora, CO USA
[8] Aegera Therapeut, Montreal, PQ, Canada
[9] Sarah Cannon Canc Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3008
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND EXPOSURE-PD RELATIONSHIPS OF THE INVESTIGATIONAL DRUG MLN8237, AN AURORA A KINASE INHIBITOR IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Zhou, X.
    Ecsedy, J.
    Danaee, H.
    Fingert, H.
    Venkatakrishnan, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S67 - S67
  • [42] A phase I study of safety, pharmacokinetics, and pharmacodynamics of SCR-6920, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced malignant tumors
    Yu, J.
    Sun, Y.
    Guo, S.
    Wang, H. Q.
    Wu, J.
    Jiang, X.
    Chen, J.
    Yang, G.
    Yang, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S474 - S474
  • [43] A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors
    LoRusso, P.
    Markman, B.
    Tabernero, J.
    Shazer, R.
    Nguyen, L.
    Heath, E.
    Patnaik, A.
    Papadopoulos, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors
    Owonikoko, Taofeek K.
    Harvey, R. Donald
    Carthon, Bradley
    Chen, Zhengjia
    Lewis, Colleen
    Collins, Hanna
    Zhang, Chao
    Lawson, David H.
    Alese, Olatunji B.
    Bilen, Mehmet Asim
    Sica, Gabriel L.
    Steuer, Conor E.
    Shaib, Walid L.
    Wu, Christina
    Harris, Wayne B.
    Akce, Mehmet
    Kudchagkar, Ragini R.
    El-Rayes, Bassel F.
    Lonial, Sagar
    Ramalingam, Suresh S.
    Khuri, Fadlo Raja
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2497 - 2505
  • [45] Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
    Soria, J. -C.
    DeBraud, F.
    Bahleda, R.
    Adamo, B.
    Andre, F.
    Dientsmann, R.
    Delmonte, A.
    Cereda, R.
    Isaacson, J.
    Litten, J.
    Allen, A.
    Dubois, F.
    Saba, C.
    Robert, R.
    D'Incalci, M.
    Zucchetti, M.
    Camboni, M. G.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2014, 25 (11) : 2244 - 2251
  • [46] A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
    Soria, Jean-Charles
    De Braud, Filippo G.
    Bahleda, Ratislav
    Adamo, Barbara
    Cereda, Roberta
    Camboni, Maria Gabriella
    Robert, Renate
    Isaacson, Jeffrey D.
    Litten, Jason B.
    Allen, Andrew R.
    Rolfe, Lindsey
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.
    Burris, H. A.
    Siu, L. L.
    Infante, J. R.
    Wheler, J. J.
    Kurkjian, C.
    Opalinska, J.
    Smith, D. A.
    Antal, J. M.
    Gauvin, J. L.
    Gonzalez, T.
    Adams, L. M.
    Bedard, P.
    Gerecitano, J. F.
    Kurzrock, R.
    Moore, K. N.
    Morris, S. R.
    Aghajanian, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Phase I safety and pharmacokinetic (PK) study of sunitinib (S) in combination with ifosfamide (I) in patients (pts) with advanced solid tumors (STs)
    Hamberg, P.
    Steeghs, N.
    Loos, W. J.
    van der Biessen, D. J.
    den Hollander, M. A.
    Tascilar, M.
    Verweij, J.
    Gelderblom, H.
    Sleijfer, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study
    Takahashi, Shunji
    Fujiwara, Yutaka
    Nakano, Kenji
    Shimizu, Toshio
    Tomomatsu, Junichi
    Koyama, Takafumi
    Ogura, Mariko
    Tachibana, Masaya
    Kakurai, Yasuyuki
    Yamashita, Tomonari
    Sakajiri, Sakura
    Yamamoto, Noboru
    CANCER SCIENCE, 2021, 112 (06) : 2361 - 2370
  • [50] Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study
    Xu, Jian Ming
    Wang, Yan
    Chen, Yu Ling
    Jia, Ru
    Li, Jie
    Gong, Ji Fang
    Li, Jing
    Qi, Chuan
    Hua, Ye
    Tan, Cui Rong
    Wang, Jian
    Li, Ke
    Sai, Yang
    Zhou, Feng
    Ren, Yong Xin
    Qing, Wei Guo
    Jia, Hong
    Su, Wei Guo
    Shen, Lin
    ONCOTARGET, 2017, 8 (26) : 42076 - 42086
12345